Efficacy and safety of memantine in patients with mild to moderate vascular dementia: A randomized, placebo-controlled trial (MMM 300)

Stroke

Volumn 33, Issue 7, 2002, Pages 1834-1839

  Orgogozo, Jean Marc ^a   Rigaud, Anne Sophie ^b   Stöffler, Albrecht ^c   Möbius, Hans Jorgen ^c   Forette, Françoise ^b  

^a HÔPITAL PELLEGRIN   (France)

^b Paris Descartes University   (France)

^c MERZ PHARMACEUTICALS GMBH   (Germany)

Author keywords

Cerebral ischemia; Dementia; Glutamate; Memantine; N methyl D aspartate; Randomized controlled trials

Indexed keywords

MEMANTINE; PLACEBO;

ADULT; AGED; AGITATION; ALZHEIMER DISEASE; ARTICLE; BEHAVIOR; BRAIN ISCHEMIA; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; COGNITION; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; MULTIINFARCT DEMENTIA; NEUROTOXICITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VERTIGO;

AGED; COGNITION; DEMENTIA, VASCULAR; DISEASE PROGRESSION; DIZZINESS; DOPAMINE AGENTS; DOUBLE-BLIND METHOD; FEMALE; FRANCE; HUMANS; MALE; MEMANTINE; MIDDLE AGED; N-METHYLASPARTATE; NEUROPSYCHOLOGICAL TESTS; TREATMENT OUTCOME;

EID: 0036314492     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.0000020094.08790.49     Document Type: Article

References (43)

1. Vascular dementia: Fortnightly review
2. The chemical nature of the main central excitatory transmitter: A critical appraisal based upon release studies and synaptic vesicle localization
3. The glutamatergic system and neurodegeneration in dementia: Preventive strategies in Alzheimer's disease
4. Psychotogenicity and N-methyl-D-aspartate receptor antagonism: Implications for neuroprotective pharmacotherapy
5. Glutamate toxicity in chronic neurodegenerative disease
6. Excitatory amino acids and Alzheimer's disease
7. Glycine and N-methyl-D-aspartate receptors: Physiological significance and possible therapeutic applications
8. Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties
9. Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist - A review of preclinical data
10. Effects of the uncompetitive NMDA receptor antagonist memantine on hippocampal long-term potentiation, short-term exploratory modulation and spatial memory in awake, freely moving rats
11. Infusion of (+)-MK-801 and memantine: Contrasting effects on radial maze learning in rats with entorhinal cortex lesion
12. Memantine prevents progressive functional neuro-degeneration in rats
13. Differential effects of NMDA-receptor antagonists on long-term potentiation and hypoxic/hypoglycaemic excitotoxicity in hippocampal slices
14. Efficacy and tolerability of memantine in patients with dementia syndrome
15. Memantine in the treatment of mild to moderate dementia syndrome: A double-blind placebo-controlled study
16. Memantine in severe dementia: Results of the M-Best Study (Benefit and Efficacy in Severely Demented Patients During Treatment With Memantine)
17. Memantine in moderately severe to severe Alzheimer's disease (AD): Results of a placebo-controlled 6-month trial
18. Evaluation of memantine for neuroprotection in dementia
19. Pharmacological rationale for memantine in chronic cerebral hypoperfusion, especially vascular dementia
20. Vascular dementia: Diagnostic criteria for research studies: Report of the NINDS-AIREN International Workshop
21. Diagnostic evaluation of degenerative and vascular dementia
22. Sensitivity and specificity of newly proposed clinical criteria for possible vascular dementia
23. Mini-mental-state: A practical method for grading the cognitive state of patients for the clinician
24. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease
25. The Alzheimer's Disease Assessment Scale: An instrument for assessing treatment efficacy
26. Alzheimer's Disease Assessment Scale (ADAS)
27. Clinical global measures of dementia: Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines
28. GBS Scale
29. 028.CGI: Clinical global impressions
30. New behavioural assessment scale for geriatric out-and inpatients: The NOSGER (Nurse's Observational Scale for Geriatric Patients)
31. Research criteria for subcortical vascular dementia in clinical trials
32. Alzheimer's disease and vascular dementia: Some points of confluence
33. Vascular dementia: Disease entity or Alzheimer type lesion? Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS)
34. Overlap between pathology of Alzheimer disease and vascular dementia
35. Cognitive outcome measures
36. The cognitive syndrome of vascular dementia: Implications for clinical trials
37. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease: Donepezil Study Group
38. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: Results of an international, 26-week, multicenter, randomized placebo-controlled trial
39. Clinical trials of propentofylline in vascular dementia: European/Canadian Propentofylline Study Group
40. The Scandinavian Multi-Infarct Dementia Trial. A double-blind, placebo- controlled trial on nimodipine in multi-infarct dementia
41. Evaluation of memantine for neuroprotection in dementia
42. A prospective PMS study to validate the sensitivity for change of the D-scale in advanced stages of dementia using the NMDA-antagonist memantine